Cantor Fitzgerald Reaffirms Hold Rating for Acadia Healthcare (ACHC)
“We rate ACHC Neutral primarily to reflect our view of the uncertainty associated with the recovery of its U.K. business, which accounts for 40% of the company’s revenue. $39 price target is based on comparable-company analysis and our DCF. The Disclosure Section may be found on pages 3 – 6.Valuation Our $39 price target reflects our reservations about the company’s ability to grow both organically and through acquisitions.”,” the firm’s analyst commented.
ACHC has been the subject of several other research reports. Jefferies Financial Group lifted their price target on Acadia Healthcare from $44.00 to $47.00 and gave the company a buy rating in a research note on Tuesday, July 31st. Zacks Investment Research upgraded Acadia Healthcare from a hold rating to a buy rating and set a $48.00 price objective on the stock in a report on Tuesday, July 24th. Mizuho set a $37.00 target price on Acadia Healthcare and gave the stock a hold rating in a report on Tuesday, August 28th. Craig Hallum cut Acadia Healthcare from a buy rating to a hold rating in a report on Wednesday. They noted that the move was a valuation call. Finally, BidaskClub cut Acadia Healthcare from a buy rating to a hold rating in a report on Wednesday, August 1st. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $44.36.
Acadia Healthcare (NASDAQ:ACHC) last announced its quarterly earnings results on Monday, July 30th. The company reported $0.70 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.70. Acadia Healthcare had a return on equity of 7.93% and a net margin of 7.52%. The firm had revenue of $765.70 million during the quarter, compared to analyst estimates of $767.93 million. During the same quarter in the previous year, the business earned $0.66 EPS. Acadia Healthcare’s revenue for the quarter was up 5.5% compared to the same quarter last year. On average, sell-side analysts expect that Acadia Healthcare will post 2.52 EPS for the current year.
In other news, Director Reeve B. Waud sold 8,135 shares of the business’s stock in a transaction that occurred on Thursday, July 26th. The stock was sold at an average price of $45.00, for a total transaction of $366,075.00. Following the transaction, the director now directly owns 14,213 shares in the company, valued at approximately $639,585. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 11.10% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in ACHC. Dimensional Fund Advisors LP raised its position in shares of Acadia Healthcare by 27.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 5,153,977 shares of the company’s stock valued at $210,849,000 after buying an additional 1,122,452 shares during the period. Copper Rock Capital Partners LLC purchased a new stake in shares of Acadia Healthcare during the 2nd quarter valued at approximately $27,394,000. BlackRock Inc. raised its position in shares of Acadia Healthcare by 2.1% during the 2nd quarter. BlackRock Inc. now owns 10,336,713 shares of the company’s stock valued at $422,875,000 after buying an additional 210,999 shares during the period. State of New Jersey Common Pension Fund D raised its position in shares of Acadia Healthcare by 22.5% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 980,000 shares of the company’s stock valued at $34,496,000 after buying an additional 180,000 shares during the period. Finally, Rothschild Asset Management Inc. raised its position in shares of Acadia Healthcare by 21.9% during the 2nd quarter. Rothschild Asset Management Inc. now owns 961,308 shares of the company’s stock valued at $39,327,000 after buying an additional 172,568 shares during the period.
About Acadia Healthcare
Acadia Healthcare Company, Inc develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities. The company operates acute inpatient psychiatric facilities, which offer evaluation and crisis stabilization of patients with severe psychiatric diagnoses; specialty treatment facilities, including residential recovery facilities, eating disorder facilities, and comprehensive treatment centers that provide continuum care for adults with addictive disorders and co-occurring mental disorders; and residential treatment centers, which treat patients with behavioral disorders in a non-hospital setting, including outdoor programs.
Featured Article: Analyzing a company’s cash flow statement
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.